Division of Hematology and Oncology

May 28, 2020

Multinational consortium reports COVID-19 impact on cancer patients

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.

By Tom Wilemon
April 30, 2020

Initiative to explore COVID-19 outcomes in cancer patients

A multi-institutional consortium led by Vanderbilt-Ingram Cancer Center (VICC) is collecting data on cancer patients with COVID-19 as part of a rapid effort to understand the unique effects the coronavirus has on this vulnerable population.

By Tom Wilemon
April 23, 2020

Health workers sought for hydroxychloroquine study

Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.

By Bill Snyder
red and blue boxing gloves
March 5, 2020

One-two punch for cancer

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.

By Sanjay Mishra
February 20, 2020

Post-transplant diabetes may be reversible: study

Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.

By Bill Snyder
February 5, 2020

Vanderbilt-Ingram Cancer Center researchers included in ASCO annual report

Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.

By Tom Wilemon
February 5, 2020

Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform

Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
By Tom Wilemon
January 9, 2020

Park named interim Hematology and Oncology director

Ben Ho Park, MD, PhD, has been named interim director of the Division of Hematology and Oncology.
By Tom Wilemon
December 5, 2019

Balko lands Mary Kay Foundation grant for breast cancer research

Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.
By Tom Wilemon
December 4, 2019

Genetic screen in worms reveals critical step in insulin synthesis

The identification of a protein important for insulin synthesis may hold clues for understanding the pathogenesis of diabetes.
By Leigh MacMillan
November 6, 2019

Rathmell receives 2019 Eugene P. Schonfeld Award

The Kidney Cancer Association is recognizing the research accomplishments and leadership achievements of W. Kimryn Rathmell, MD, PhD, with its top honor, the Eugene P. Schonfeld Award.
By Tom Wilemon
November 1, 2019

New Physician Spotlight: Cathy Eng

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, was recruited to VUMC from The University of Texas MD Anderson Cancer Center in Houston.
By VUMC News and Communications
October 24, 2019

Urologic cancer expert Rini joins VICC as chief of Clinical Trials

Brian Rini, MD, an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development, is joining Vanderbilt-Ingram Cancer Center as the inaugural chief of Clinical Trials.
By Tom Wilemon
1 … 5 6 7 8 9 … 13